Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Nuvectis Pharma Inc (OQ:NVCT)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily
May 16, 2024 08:30 am ET
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
May 07, 2024 08:00 am ET
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Apr 08, 2024 08:30 am ET
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor...
Mar 19, 2024 08:00 am ET
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Mar 15, 2024 08:00 am ET
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
Mar 14, 2024 09:00 am ET
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma, Inc. (NASDAQ: NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. The NXP800...
Mar 05, 2024 08:00 am ET
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Feb 09, 2024 08:32 am ET
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Feb 09, 2024 08:00 am ET
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Jan 03, 2024 08:00 am ET
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Dec 18, 2023 08:00 am ET
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Nov 08, 2023 08:00 am ET
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Oct 24, 2023 08:00 am ET
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Sep 25, 2023 07:30 pm ET
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Sep 21, 2023 08:00 am ET
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Sep 12, 2023 08:00 am ET
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Sep 06, 2023 08:00 am ET
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Sep 01, 2023 08:00 am ET
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Aug 17, 2023 08:00 am ET
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Aug 09, 2023 08:00 am ET
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Jun 20, 2023 08:00 am ET
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
May 15, 2023 08:00 am ET
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
May 10, 2023 08:00 am ET
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Apr 27, 2023 10:14 am ET
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023.  The complete, corrected release follows:  Nuvectis Pharma, Inc. (“Nuvectis”,...
Apr 27, 2023 08:00 am ET
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
Apr 18, 2023 08:00 am ET
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Apr 10, 2023 08:00 am ET
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Mar 17, 2023 08:00 am ET
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Mar 10, 2023 08:00 am ET
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
Mar 07, 2023 08:00 am ET
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Feb 23, 2023 08:00 am ET
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Feb 09, 2023 08:00 am ET
Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to
Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Jan 04, 2023 08:00 am ET
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,...
Dec 01, 2022 08:00 am ET
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced...
Nov 08, 2022 08:00 am ET
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
enabling studies for NXP900 are ongoing, submission of IND or equivalent expected in Q1 2023Positive preclinical data for NXP800 in an ARID1a-mutated gastric cancer modelNXP800 poster presented at the 2022 ENA Conference on the validation of...
Oct 18, 2022 08:00 am ET
Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced...
Oct 03, 2022 04:30 pm ET
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s...
Sep 28, 2022 08:00 am ET
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a...
Sep 13, 2022 08:30 am ET
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced positive data for...
Sep 07, 2022 08:30 am ET
Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
Aug 05, 2022 08:00 am ET
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of novel therapies for the treatment of serious conditions of unmet medical need in oncology, today reported its financial...
Aug 01, 2022 08:30 am ET
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced...
Jul 27, 2022 08:00 am ET
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into...
Jun 21, 2022 08:15 am ET
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food...
Jun 13, 2022 08:30 am ET
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced positive data for...
May 20, 2022 10:21 am ET
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
May 10, 2022 08:30 am ET
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today reported its financial results for the...
Apr 13, 2022 08:30 am ET
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the poster...
Apr 11, 2022 08:30 am ET
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the oral...
Mar 22, 2022 08:30 am ET
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”) is a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology today reported its financial results for...
Mar 10, 2022 08:30 am ET
Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to...
Mar 09, 2022 10:12 am ET
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur,...
Feb 22, 2022 08:30 am ET
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced a publication in Cancer...
Feb 08, 2022 01:00 pm ET
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology, today announced the closing of its...
Feb 04, 2022 09:30 am ET
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology, today announced the pricing of...